NovaBridge Biosciences(NBP)Earnings, Financials & Key RatiosNovaBridge Biosciences (NBP) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2025Q4
the company's limited $30.1 million cash position and lack of recurring revenue suggest a high probability of near-term capital raises and shareholder dilution to fund ongoing operations.
NovaBridge Biosciences (NBP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
NovaBridge Biosciences (NBP) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 30, 2026 | $0.11vs $0.01-1280.2% | — |
| Q2 2026 | Apr 7, 2026 | $0.22vs $0.04-528.6% | — |
| Q2 2026 | Apr 2, 2026 | $0.03vs $0.01-529.0% | — |
| Q4 2025 | Dec 18, 2025 | $0.25vs $0.01-1801.1% | — |
Recent stock market news and headlines for NovaBridge Biosciences (NBP)
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026.
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026 Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas (GEA) whose tumors are both Claudin 18.2 (CLDN18.2) and PD-L1 positive.
Key metrics vs top competitors for NovaBridge Biosciences (NBP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.02 | $101.23M | -12.63 | — | — | -0.88% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $27.67 | $3.46B | -212.85 | 91.34% | -0.57% | -1.41% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — |
NovaBridge Biosciences (NBP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NBP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NovaBridge Biosciences (NBP) stock FAQ — growth, dividends, profitability & financials explained
NovaBridge Biosciences (NBP) reported a net loss of $19.9M for fiscal year 2025.
NovaBridge Biosciences (NBP) has a return on equity (ROE) of -0.9%. Negative ROE indicates the company is unprofitable.
NovaBridge Biosciences (NBP) had negative free cash flow of $1.4M in fiscal year 2025, likely due to heavy capital investments.
